Momenta and Mylan reported unexpected results for proposed Orencia biosimilar

November 10, 2017 6:14 AM

momenta-mylan-biosimilarnews-logo

Momenta Pharmaceuticals, Inc. and Mylan N.V. have last week announced that M834, a proposed biosimilar of Orencia (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in the Phase I study.

The study was conducted to compare the pharmacokinetics, safety and immunogenicity of M834 to US- and EU-sourced Orencia in normal healthy volunteers. Momenta and Mylan continue to gather and analyze these data to inform next steps for the program.

“This was an unexpected result and we are disappointed with the outcome of this PK study,” said Craig Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “We are in the process of gathering the full data set and will work with Mylan to fully analyze these data to better understand the study results and evaluate next steps for this program. We remain committed to executing on our biosimilar portfolio.”

The Phase I study was a randomized, double-blind, three-arm, parallel group, single-dose subcutaneous administration clinical study to compare the pharmacokinetics, safety, and immunogenicity of M834, US-sourced Orencia, and EU-sourced Orencia in 243 normal healthy volunteers.

Orencia is a fusion protein and the only CTLA-4Ig approved in the US, EU, and Japan for the treatment of Rheumatoid Arthritis and in the US and EU for the treatment of Psoriatic Arthritis and Juvenile Idiopathic Arthritis. In 2016, worldwide sales of Orencia totaled $2.4 billion.

 

Source: Momenta Pharmaceuticals

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!